Phase 3 Clinical Trial Comparing the Safety and Efficacy of BMS-986393 to Standard of Care Regimens in Patients with Relapsed/Refractory Multiple Myeloma

Phase 2 Study of BMS-986393, a GPRC5D-directed CART-Cell Therapy, in Participants with Relapsed or Refractory Multiple Myeloma

Phase 3 Clinical Trial Comparing the Safety and Efficacy of Belantamab Mafodotin, Lenalidomide and Dexamethasone Versus Daratumumab, Lenalidomide and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma who are Ineligible for Autologous Stem Cell Transplant

Phase 3 Clinical Trial Comparing Iberdomide VS Lenalidomide as Maintenance Therapy Following Autologous Stem Cell Transplant in Participants with Newly Diagnosed Multiple Myeloma

A Phase 1 Study to Evaluate the Safety of KLN-1010, a Novel, In Vivo Gene Therapy to Generate Anti-B Cell Maturation Antigen (Anti-BCMA) Chimeric Antigen Receptor-T Cells (CAR-T) in Patients With Relapsed and Refractory Multiple Myeloma

A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

Personalized Autologous Transplant for Multiple Myeloma

A Phase 1B, Open-Label Study of Elranatamab in Combination with Iberdomide in Participants with Relapsed Refractory Multiple Myeloma